SynthesisMolecular diagnosis & therapy2021
The Diagnostic Accuracy of miR-371a-3p for Testicular Germ Cell Tumors: A Systematic Review and Meta-Analysis.
Synthesis in Molecular diagnosis & therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Diagnostic performance of the microRNA-371a assay in small testicular masses: a real-world cohort study.BJU international · 2026Article
- MicroRNAs and immunotherapy in testicular germ cell tumors: opportunities and challenges for modulation of the immune microenvironment.Frontiers in immunology · 2026Review
- Circulating miRNAs in genitourinary cancer: pioneering advances in early detection and diagnosis.The journal of liquid biopsy · 2025Review
- Potential next generation markers of testicular germ cell tumors: miRNA-371a-3p.International urology and nephrology · 2025Review
- Advancing GCT Management: A Review of miR-371a-3p and Other miRNAs in Comparison to Traditional Serum Tumor Markers.Cancers · 2024Review
- Refining the serum miR-371a-3p test for viable germ cell tumor detection.Scientific reports · 2023Article
- Refining the serum miR-371a-3p test for viable germ cell tumor detection: identification and definition of an indeterminate range.Research square · 2023Article
- The utility of cfDNA in TGCT patient management: a systematic review.Therapeutic advances in medical oncology · 2022Review
- Referring to the article published on pp. 400-406 of this issue: Progress and challenges in testicular cancer microRNAs.Asian journal of urology · 2021Article
- Comparative Analyses of Liquid-Biopsy MicroRNA371a-3p Isolation Protocols for Serum and Plasma.Cancers · 2021Article
- Improving outcomes in germ cell cancers using miRNA.Therapeutic advances in medical oncology · 2021Review
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study sought to assess the utility of miR-371a-3p levels as a tool for diagnosing testicular germ cell tumors.
methodsFor this systematic review and meta-analysis we reviewed available published studies assessing the accuracy of miR-371a-3p as a tool for diagnosing testicular germ cell tumors. STATA 16.0 was used to calculate pooled sensitivity, specificity, negative likelihood ratio (NLR), positive likelihood ratio (PLR), and area under the curve (AUC) values.
resultsIn total, six studies incorporating 1835 individuals were included in this analysis. Pooled results suggested that miR-371a-3p was able to differentiate between testicular germ cell tumors and non-testicular germ cell tumors or healthy individuals with a sensitivity of 0.90 [95% confidence interval (CI) 0.88-0.92], a specificity of 0.93 (95% CI 0.87-0.96), a PLR of 12.2 (95% CI 6.90-18.24), an NLR of 0.11 (95% CI 0.09-0.14) a diagnostic odds ratio (DOR) of 121.56 (95% CI 64.84-227.89), and an AUC of 0.94.
conclusionsMiR-371a-3p represents a viable biomarker associated with testicular germ cell tumors.
Indexed as
Identifiers
33886084What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.